Alnylam Stock Slides as Rival's Trial Failure Raises Concerns for Gene-Silencing Drugs

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) dropped nearly 4.9% in pre-market trading after new clinical data for a rival drug raised investor concerns about the company's own pipeline and therapeutic approach.

Rival's Trial Data Fuels Class-Wide Doubts

The primary catalyst for the decline was the formal presentation of full Phase 3 trial data for Wainua (eplontersen), a drug developed by AstraZeneca and Ionis, at the European Society of Cardiology Congress 2026. The detailed results from the CARDIO-TTRansform study reinforced the drug's previously announced top-line failure in treating transthyretin amyloid cardiomyopathy (ATTR-CM).

Because Wainua is a gene-silencing therapy, its failure has negative implications for Alnylam's lead drug, Amvuttra (vutrisiran), which uses a similar RNA-silencing mechanism. The data fueled concerns that this class of drugs may not provide significant cardiovascular benefits for patients already on TTR stabilizers, which are the current standard of care.

Analyst Downgrade and Competitive Headwinds

Ad

Adding to the selling pressure, analysts at Wells Fargo cut their price target on Alnylam stock to $256 from a previous $316. This follows other recent analyst revisions and an existing overhang from the company's July 30 earnings report.

During that report, Alnylam management lowered its full-year 2026 net product revenue guidance for its TTR franchise to a range of $4.2 billion to $4.5 billion, citing a slowdown in patient volumes. The competitive environment is also intensifying, with BridgeBio's stabilizer drug, Attruby, gaining traction and projected to surpass $1 billion in sales in 2026.

Market Impact

The combination of the negative clinical read-through from the ESC Congress, the fresh analyst price target cut, and unresolved concerns from the prior guidance reduction drove the stock sharply lower. The decline pushed Alnylam's shares toward the lower end of their 52-week range of $197.81 to $495.55, according to Investing.com.